The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

June 15, 2017 • By Simon M. Helfgott, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Congress, the ball and the stick are back in your court. Are you prepared to use either?

You Might Also Like
  • Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
  • When Will Generic Biologic Drugs Become Commercially Available?
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
Explore This Issue
June 2017
Also By This Author
  • Inflammatory Origin of Fever Is Key to Diagnosis

Simon M. Helfgott, MDSimon M. Helfgott, MD, is associate professor of medicine in the Division of Rheumatology, Immunology and Allergy at Harvard Medical School in Boston.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Russo E. Special report: The birth of biotechnology. Nature. 2003 Jan;421:456–457.
  2. Whalen J. Why the U.S. pays more than other countries for drugs. The Wall Street Journal. 2015 Dec 1.
  3. Raymond N. Martin Shkreli, who raised drug prices from $13.50 to $750, arrested in securities fraud probe. Scientific American. (n.d.).
  4. Cuprimine prices, coupons and patient assistance programs. Drugs.com. 2017 May 2 (updated).
  5. Gray RES, Doherty SM, Galloway J, et al. A double blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum. 1991 Mar;34(3):287–295.
  6. Johnson CY. An old drug gets a new price to fight a rare disease: $89,000 a year. The Washington Post. 2017 Feb 10.
  7. Morgensen G. To stop price spikes on prescription drugs, a widening radar. The New York Times. 2016 Dec 23.
  8. Walker J. Drugmakers point finger at middlemen for rising drug prices. The Wall Street Journal. 2016 Oct 3.
  9. Chen C. Drugmakers are trying a new strategy: Charging less. Bloomberg. 2017 Mar 30.
  10. Clerici JM. Federal gov’t won’t march in when it comes to drug prices. Law 360. 2016 Jul 11.
  11. Li D, Azoulay P, Sampat BN. The applied value of public investments in biomedical research. Science. 2017 Apr 7;356(6333):78–81.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Biologics & Biosimilars, Rheuminations Tagged With: biologic, biosimilar, biotechnology, Congress, DNA, drug cost, drug therapy, patient care, Research, Rheumatic Disease, rheumatologist, rheumatology, TreatmentIssue: June 2017

You Might Also Like:
  • Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
  • When Will Generic Biologic Drugs Become Commercially Available?
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
  • Transatlantic Divide: How U.S. Pays Three Times More for Drugs

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.